局部外用咪喹莫特联合白蛋白结合型紫杉醇治疗乳腺癌皮肤转移:一项2期临床试验
这项单臂2期临床试验纳入15例既往治疗后胸壁复发的乳腺癌患者,评估局部外用5%咪喹莫特联合白蛋白结合型紫杉醇的安全性和客观缓解率。14例可评估患者中,5例(36%)完全缓解,5例(36%)部分缓解,总缓解率为72%(14例中10例),但缓解持续时间有限。治疗相关不良事件以低级别为主,358例不良事件中330例(92%)为1级和2级。
要点
- 14例可评估患者中总缓解率为72%(10/14),完全缓解和部分缓解各5例(36%)。
- 358例不良事件中330例(92%)为1级和2级,联合治疗与低级别毒性相关。
- 治疗前PD-1+CD4+、PD-1+CD8+外周血T细胞及mMDSC水平高于对照者预测临床应答欠佳。
核心结论
- TLR-7激动剂联合白蛋白结合型紫杉醇的化学免疫调节可有效诱导治疗难治性乳腺癌胸壁转移病灶消退,但缓解持续时间短。
- 治疗前存在提示T细胞耗竭或全身免疫抑制的细胞水平可能作为筛选应答患者的标志物。
研究设计与样本
- 单臂2期临床试验,纳入15例2009年至2012年间在学术医疗中心接受过治疗、胸壁疾病复发的乳腺癌患者。
主要发现
- 15例受试者基线中位年龄为54岁(范围46-92岁),其中14例可评估。
- 14例可评估患者中5例(36%)达到完全缓解,另5例(36%)为部分缓解,总缓解率为72%(10/14)。
- 358例不良事件中330例(92%)为1级和2级。
- 治疗前PD-1+CD4+外周血T细胞(95%CI,2.68-6.63;P<.001)、PD-1+CD8+外周血T细胞(95%CI,1.13-8.35;P=.01)及单核细胞髓源性抑制细胞(mMDSC)(95%CI,3.62-12.74;P=.001)水平高于对照者预测临床应答欠佳。
关键数值与推荐
- 咪喹莫特5%乳膏局部用于指定靶病灶,在28天周期的第1至4天、第8至11天、第15至18天及第22至25天每日1次,持续12周。
- 白蛋白结合型紫杉醇100 mg/m2静脉给药,于第1、8、15天给药,每28天重复一次,持续12周。
- 主要终点为安全性和客观缓解率,次要终点包括肿瘤浸润淋巴细胞的产生和免疫细胞群的调节。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缓解持续时间有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Salvage chemotherapy for recurrent chest wall lesions in breast cancer results in response rates of 20% to 30%. Preclinical studies showed significant disease regression could be induced in murine chest wall mammary cancers with a topical toll-like receptor (TLR)-7 agonist, imiquimod. OBJECTIVE: To evaluate the safety and objective response rate (ORR) of imiquimod in combination with systemic albumin bound paclitaxel in treatment-refractory breast cancer of the chest wall. DESIGN, SETTING, AND PARTICPANTS: A single arm phase 2 clinical trial of 15 patients with breast cancer previously treated in an academic medical center setting between 2009 and 2012 for chest wall disease that had recurred. INTERVENTIONS: Imiquimod cream, 5%, was applied topically to a designated target lesion once per day for 4 consecutive days on days 1 through 4, 8 through 11, 15 through 18, and 22 through 25 of a 28-day cycle, for 12 weeks. Albumin bound paclitaxel, 100 mg/m2, was given intravenously on days 1, 8, and 15, and repeated every 28 days over the 12-week period. MAIN OUTCOMES AND MEASURES: The primary endpoint was safety and ORR. Secondary endpoints included the generation of tumor-infiltrating lymphocytes and modulation of immune cell populations. RESULTS: The median age at baseline of the 15 study participants was 54 years (range, 46-92 years). Fourteen patients were evaluable. Combination therapy was associated with low-grade toxic effects. Of 358 adverse events 330 (92%) were grades 1 and 2. Five (36%) patients achieved a compete response and another 5 (36%) were partial responders for an overall response rate of 72% (10 of 14). The response duration was limited. Pretreatment levels of programmed death-1 (PD-1)+ peripheral blood T cells (PD-1+ cluster of differentiation [CD]4+; 95% CI, 2.68-6.63; P < .001 and PD-1+CD8+; 95% CI, 1.13-8.35; P = .01) and monocytic myeloid derived suppressor cells (mMDSC) (95% CI, 3.62-12.74; P = .001) greater than controls predicted suboptimal clinical response. CONCLUSIONS AND RELEVANCE: Chemoimmunomodulation with a TLR-7 agonist and albumin bound paclitaxel is effective in inducing disease regression in treatment-refractory breast cancer chest wall metastases but responses are short-lived. Preexisting levels of cells indicating either T-cell exhaustion or systemic immunosuppression may be markers of selection for responsive patients. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00821964.
引用
- Salazar LG, Lu H, Reichow JL, et al. Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases: A Phase 2 Clinical Trial. JAMA Oncol. 2017. PMID: 28114604. doi:10.1001/jamaoncol.2016.6007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。